DCTH · Delcath Systems, Inc. · Executive Compensation

$14.75 +0.24 (+1.65%) At close · Oct 27 Q2 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$511.81M

34.70M

Volume · Oct 27 245.08K Avg daily vol (3M) 466.69K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$635,707	—	—	$4,774,551	$355,000	—	$5,765,258
Vojislav Vukovic	Chief Medical Officer	$488,000	—	—	$1,383,395	$184,000	—	$2,055,395
Martha Rook	Chief Operating Officer	$460,833	—	—	$1,383,395	$180,000	—	$2,024,228

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$560,622	—	—	$1,230,036	$366,756	—	$2,157,414
Vojislav Vukovic	Chief Medical Officer	$465,000	—	—	$410,012	$210,600	—	$1,085,612
Martha Rook	Chief Operating Officer	$336,458	—	—	$445,625	$151,014	—	$933,097

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$538,078	—	—	$1,792,348	$189,888	—	$2,520,314
John Purpura	M.S. Chief Operating Officer	$409,229	—	—	$663,821	$129,977	—	$1,203,027
Kevin Muir	General Manager, Interventional Oncology	$316,272	—	—	$621,582	$78,130	—	$1,015,984
Vojislav Vukovic	Chief Medical Officer	—	—	—	—	—	—	—
Martha Rook	Chief Operating Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$521,024	—	—	$800,499	$131,175	$19,500	$1,472,198
John Purpura	M.S. Chief Operating Officer	$396,136	—	—	$318,407	$89,785	—	$804,328
Johnny John	Senior Vice President, Clinical Development and Medical Affairs	$393,023	$79,140	—	$265,341	—	—	$737,504
Kevin Muir	General Manager, Interventional Oncology	—	—	—	—	—	—	—
General Manager	Interventional Oncology	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$475,151	$130,666	—	$1,230,585	—	$78,000	$1,914,402
John Purpura	Chief Operating Officer	$386,823	$95,739	—	$442,927	—	—	$925,489
Johnny John	Senior Vice President, Clinical Development and Medical Affairs	$325,557	$58,078	—	$492,142	—	—	$875,777

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gerard Michel	Chief Executive Officer	$112,500	—	—	$5,629,000	—	$19,500	$5,761,000
John Purpura	Chief Operating Officer	$347,500	$57,870	—	$1,981,900	—	$32,000	$2,419,270
Johnny John	M.D., Senior Vice President Clinical Development and Medical Affairs	$256,632	$23,740	—	$849,395	—	—	$1,129,767
Christine Padula	Interim Principal Accounting Officer	$160,800	$15,000	—	$226,500	—	$24,500	$426,770
Jennifer K. Simpson	former President/CEO	$253,322	—	—	—	—	—	$253,322

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jennifer K. Simpson	former President/CEO	$466,594	$508,495	—	$90,706	—	—	$1,065,795
Barbra Keck	M.B.A. Former Chief Financial Officer	$324,000	$311,449	—	$64,790	—	—	$700,239
John Purpura	Chief Operating Officer	$335,000	$288,151	—	$59,390	—	—	$682,541
Gerard Michel	Chief Executive Officer	—	—	—	—	—	—	—
Christine Padula	Interim Principal Accounting Officer	—	—	—	—	—	—	—

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jennifer K. Simpson	Former President and Chief Executive Officer	$466,594	$75,000	—	—	—	—	$541,594
John Purpura	M.S., Chief Operating Officer	$335,000	$50,000	—	—	—	—	$385,000
Barbra Keck	M.B.A. Former Chief Financial Officer	$324,000	$50,000	—	—	—	—	$374,000

Executive changes

Person	Role	Change	Effective	Filed
John R. Sylvester	Class II director	Appointed	2026-05-13	2026-05-14
Elizabeth Czerepak	Class II director	Appointed	2026-05-13	2026-05-14
Gilad Aharon	Class I director	Appointed	2025-05-15	2025-05-16
Gerard Michel	Class I director	Appointed	2025-05-15	2025-05-16
Bridget Martell	Class III Director	Appointed	2024-05-23	2024-05-29
Roger Stoll	Board	Retired	2024-05-23	2024-05-29
Martha S. Rook	Chief Operating Officer	Appointed	2024-03-18	2024-03-19
John Purpura	Chief Operating Officer	Retired	—	2024-02-14
John R. Sylvester	Class II directors	Appointed	2023-06-12	2023-06-13
Elizabeth Czerepak	Class II directors	Appointed	2023-06-12	2023-06-13
Sandra Pennell	Senior Vice President of Finance and principal financial and accounting officer	Appointed	2023-06-01	2023-06-07

Leadership

Gerard Michel CEO, Board Member
John Purpura CEO
Sandra Pennell CFO
Martha Rook COO
Martha S. Rook COO
David Hoffman General Counsel
Christine Padula Chief Accounting Officer
Bridget Martell Board Member
Bridget Martell, M.A. M.D. Board Member
Elizabeth Czerepak Board Member
Gilad Aharon Board Member
John R. Sylvester Board Member
Roger G. Stoll Board Member
Steven Salamon Board Member

Key facts CIK 872912 CUSIP 24661P807 13F (30d) 22 filings 22 filers Visit website Investor relations